Prescribed Reading: What we know from BIO

05:04 EDT 23 Jun 2017 | BioPharmaDive

A closer look at the trends everyone was talking about at BIO, FDA continues its approval spree and Novartis has heart

Original Article: Prescribed Reading: What we know from BIO


More From BioPortfolio on "Prescribed Reading: What we know from BIO"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...